Top View
- A Feasibility Study of Multiple Cycle Therapy with Melphalan, Thiotepa
- Bladder Cancer: Current Optimal O N Intravesical Treatment T I Donald L
- DRUG NAME: Thiotepa
- Four-Cycle High-Dose Therapy with Hematopoietic Support for Metastatic Breast Cancer: No Improvement in Outcomes Compared with Single-Course High-Dose Therapy
- Emetogenic Potential of Antineoplastic Agents
- Handling Cytostatic Drugs: Contents
- A New Multidrug Reinduction Protocol with Topotecan, Vinorelbine
- Chemotherapy Protocol LYMPHOMA Matrix
- Thiotepa (Thioplex®) (“THYE‐Oh‐TEP‐A”)
- Safety and Efficacy of Thiotepa-Based Conditioning for Allogeneic Transplantation in AML: a Survey from the ALWP of the EBMT
- A Phase IIA Study of the Addition of Temozolomide
- Hematopoietic Stem Cell Transplantation in Thalassemia Major and Sickle Cell Disease: Indications and Management Recommendations from an International Expert Panel
- Oncology Medications Policy (1403)
- Breast Cancer High-Dose Thiotepa, Melphalan and Carboplatin
- Therapeutic Polymeric Nanoparticle Compositions
- Effects of Fluorouracil and Fluorouridine on Protein Synthesis in Rabbit Retina
- Changes Produced in the Urothelium by Traditional and Newer Therapeutic
- Thiotepa for Injection, Usp
- Matrix (High Dose METHOTREXATE, High Dose CYTARABINE, RITUXIMAB and THIOTEPA)
- MATRIX (Methotrexate, Cytarabine, Thiotepa and Rituximab)
- Breast Cancer Phase II Trial of Sequential High-Dose
- BRAIN CANCER TREATMENT REGIMENS (Part 1 of 9) Clinical Trials: the NCCN Recommends Cancer Patient Participation in Clinical Trials As the Gold Standard for Treatment
- Clinical Challenges in Caring for Patients with Diabetes and Cancer
- 240 DNA Methyltransferase Inhibitor CDA-2 Synergizes with High-Dose Thio
- Phase I/Pharmacokinetic RééValuationofthiotepa1
- Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients
- INJECTABLE CHEMOTHERAPY DRUGS: APPLICATION of NCCN CLINICAL PRACTICE GUIDELINES Policy Number: CANCER 009.18 T2 Effective Date: June 1, 2018
- Emetic Risk of Single Intravenous Antineoplastic Agents in Adults
- Standard Oncology Criteria Policy Number: Pending
- Tepadina, INN- Thiotepa
- TVCN Blank Document
- NIOSH Alert: Preventing Occupational Exposures to Antineoplastic
- High-Dose Methotrexate-Based Regimens and Post-Remission
- BHS Guidelines for Primary Central Nervous System Lymphoma
- Chemotherapy and Other Hazardous Drugs: Safe Use Guidelines
- Vivida Health Specialty Pharmacy Drugs (Injectable) Prior-Authorization Requirements Effective 1/1/19
- Primary Central Nervous System Lymphoma: a Narrative Review of Ongoing Clinical Trials and Goals for Future Studies
- Full Text (PDF)
- Thiotepa-Clofarabine-Busulfan with Allogeneic Stem Cell Transplant for High Risk Malignancies
- Pharmacodynamics of Mitomycin C in Cultured Human Bladder Tumors1
- TEPADINA, INN-Thiotepa
- BC Cancer Protocol Summary for Solid Tumours Using Intrathecal Methotrexate And/Or Thiotepa And/Or Cytarabine
- Group Benefit Changes for PPO Plans Effective April 1, 2019 Upon Your Group's Renewal • Clarified Precertification Requireme
- Hematopoietic Stem Cell Transplant (HSCT) As a Cure for Sickle Cell Disease
- Hazardous Drug List
- Medications That Are Considered Hazardous
- Double-Conditioning Regimens Consisting of Thiotepa, Melphalan and Busulfan with Stem Cell Rescue for the Treatment of Pediatric Solid Tumors
- TEPADINA (Thiotepa) for Injection, for Intravenous, Intracavitary, Or for Injection: 15 Mg, Lyophilized White Powder in Single-Dose Vial for Intravesical Use
- Antineoplastic Drugs